TABLE 1 MODERATE GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, ($MILLION)
TABLE 2 MODERATE GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (TONNE)
TABLE 3 RAPID GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, ($MILLION)
TABLE 4 RAPID GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (TONNE)
TABLE 5 DIMINISHING GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, ($MILLION)
TABLE 6 DIMINISHING GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 - 2026, (TONNE)
TABLE 7 IVIG PRODUCTS COMMERCIALIZED IN MARKET
TABLE 8 USFDA INDICATIONS FOR IVIG
TABLE 9 EMA APPROVED INDICATIONS FOR IVIG
TABLE 10 IGG SUBCLASS
TABLE 11 FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
TABLE 12 DISEASE ASSOCIATE WITH IGG SUBCLASS DEFICIENCY
TABLE 13 CLINICAL TRIALS FOR INTRAVENOUS IMMUNOGLOBULIN (2011-2014)
TABLE 14 PATENT ANALYSIS- UNITED STATES (2010-2014)
TABLE 15 PATENT ANALYSIS- EUROPE (2010-2014)
TABLE 16 WORLD AGING POPULATION 2013
TABLE 17 GLOBAL IVIG MARKET, BY APPLICATION, 2014-2021, $MILLION
TABLE 18 GLOBAL IVIG MARKET, BY APPLICATION, 2014-2021, (TONNE)
TABLE 19 COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
TABLE 20 HYPOGAMMAGLOBULINEMIA IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
TABLE 21 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
TABLE 22 PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY
TABLE 23 IMMUNODEFICIENCY DISEASES IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
TABLE 24 IVIG PRODUCTS FOR CONGENITAL AIDS
TABLE 25 CONGENITAL AIDS IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
TABLE 26 CLL STATISTICS 2011-2014
TABLE 27 CHRONIC LYMPHOCYTIC LEUKAEMIA IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
TABLE 28 MYASTHENIA GRAVIS IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
TABLE 29 MULTIFOCAL MOTOR NEUROPATHY IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
TABLE 30 ITP TREATMENT OPTIONS
TABLE 31 ITP IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
TABLE 32 KAWASAKI DISEASE PATIENTS PER 100,000 CHILDREN IN 2010
TABLE 33 KAWASAKI DISEASE IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
TABLE 34 GUILLAIN-BARRE SYNDROME IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
TABLE 35 OTHER IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
TABLE 36 GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2021, ($MILLION)
TABLE 37 GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2021, (TONNE)
TABLE 38 NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2021, ($ MILLION)
TABLE 39 NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
TABLE 40 EUROPE IVIG MARKET, BY COUNTRY, 2014-2021, ($ MILLION)
TABLE 41 EUROPE IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
TABLE 42 HIGH PRIORITY INDICATIONS OF IVIG
TABLE 43 COST OF IVIG PRODUCTS IN UK
TABLE 44 PRODUCTS CONTAINING IVIG IN ITALIAN MARKET
TABLE 45 ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2021, ($MILLION)
TABLE 46 ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
TABLE 47 IMMUNOGLOBULIN BRANDS AND ITS MANUFACTURERS
TABLE 48 LAMEA IVIG MARKET, BY COUNTRY, 2014-2021, ($ MILLION)
TABLE 49 LAMEA IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
TABLE 50 BIOTEST AG SANPSHOT
TABLE 51 OPERATING BUSINESS SEGMENT OVERVIEW
TABLE 52 OCTAPHARMA AG SNAPSHOT
TABLE 53 OCTAPHARMA AG OPERATING BUSNIESS OVERVIEW
TABLE 54 BAXTER INTERNATIONAL INC. SNAPSHOT
TABLE 55 OPERATING BUSINESS SEGMENTS OVERVIEW
TABLE 56 LFB BIOTECHNOLOGIES OPERATING SEGMENT OVERVIEW
TABLE 57 CHINA BIOLOGIC PRODUCTS INC. SNAPSHOT
TABLE 58 CHINA BIOLOGIC PRODUCTS INC. OPERATING BUSINESS SEGMENT OVERVIEW
TABLE 59 GRIFOLS S.A SNAPSHOT
TABLE 60 GRIFOLS S.A OPERATING SEGEMENTS
TABLE 61 KEDRION INC. SNAPSHOT
TABLE 62 KEDRION BIOPHARMA OPERATING SEGMENTS
TABLE 63 CSL BEHRING SNAPSHOT
TABLE 64 CSL BEHRING OPERATING SEGMENTS
TABLE 65 BDI PHARMA INC SNAPSHOT
TABLE 66 BDI PHARMA OPERATING SEGMENTS
TABLE 67 BAYER HEALTHCARE COMPANY SNAPSHOT
LIST OF FIGURE
FIG. 1 IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN MODERATE GROWTH SCENARIO
FIG. 2 IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN RAPID GROWTH SCENARIO
FIG. 3 IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN DIMINISHING GROWTH SCENARIO
FIG. 4 PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IVIG THERAPY
FIG. 5 TOP FACTORS IMPACTING GLOBAL IVIG MARKET (2015-2021)
FIG. 6 TOP INVESTMENT POCKETS - GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET
FIG. 7 PORTER'S FIVE FORCES ANALYSIS
FIG. 8 VALUE CHAIN ANALYSIS OF GLOBAL IVIG MARKET
FIG. 9 MARKET SHARE ANALYSIS - GLOBAL IVIG MARKET 2014
FIG. 10 PATENT ANALYSIS BY GEOGRAPHY (2011-2014)
FIG. 11 U.S. PATENT ANALYSIS BY COMAPANY (2011-2014)
FIG. 12 EUROPE PATENT ANALYSIS, BY COMPANY (2011-2014)
FIG. 13 INCIDENCES OF HAEMOPHILIA, 2010
FIG. 14 BIOTEST AG FINANCIAL PERFORMANCE BY PRODUCT SEGMENTS (2013)
FIG. 15 BIOTEST AG FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)
FIG. 16 SWOT ANALYSIS OF BIOTEST AG
FIG. 17 SWOT ANALYSIS OF OCTAPHARMA AG
FIG. 18 BAXTER INTERNATIONAL INC. FINANCIAL PERFORMANCE BY PRODUCT SEGMENTS (2013)
FIG. 19 BAXTER INTERNATIONAL INC. FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)
FIG. 20 SWOT ANALYSIS OF BAXTER INTERNATIONAL INC
FIG. 21 L FB BIOTECHNOLOGIES FINANCIAL PERFORMANCE BY PRODUCT SEGMENT (2013)
FIG. 22 LFB BIOTECHNOLOGIES FINANTIAL PERFORMANCE BY GEOGRAPHY (2013)
FIG. 23 SWOT ANALYSIS OF LFB BIOTECHNOLOGIES
FIG. 24 CHINA BIOLOGIC PRODUCTS INC. FINANCIAL PERFORMANCE BY SEGMENTS
FIG. 25 SWOT ANALYSIS OF CHINA BIOLOGIC PRODUCTS INC.
FIG. 26 FINANCIAL OF GRIFOLS S.A BY GEOGRAPHY (2013)
FIG. 27 FINANCIAL GRIFOLS S.A. BY PRODUCT GROUPS (2013)
FIG. 28 SWOT ANALYSIS OF GRIFOLS S.A.
FIG. 29 FINANCIAL REVENUE OF KEDRION BIOPHARMA GEOGRAPHY (2013)
FIG. 30 FINANCIAL KEDRION BIOPHARMA. BY PRODUCT GROUPS (2013)
FIG. 31 SWOT ANALYSIS OF KEDRION BIOPHARMA
FIG. 32 CSL BEHRING FINANCIAL REVENUE OF BY GEOGRAPHY (2013)
FIG. 33 CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)
FIG. 34 SWOT ANALYSIS OF CSL BEHRING
FIG. 35 SWOT ANALYSIS OF BDI PHARMA
FIG. 36 FINANCIAL REVENUE OF BAYER HEALTHCARE (2013 AND 2012)
FIG. 37 FINANCIALS OF BAYER HEALTHCARE, BY SEGMENTS, 2013
FIG. 38 SWOT ANALYSIS OF BAYER HEALTHCARE
